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Abstract
 The low population-prevalence of trachomatous trichiasis andBackground:
high prevalence of trachomatous inflammation–follicular (TF) provide
contradictory estimates of the magnitude of the public health threat from
trachoma in the Solomon Islands. Improved characterisation of the biology of
trachoma in the region may support policy makers as they decide what
interventions are required. Here, age-specific profiles of anti-Pgp3 antibodies
and conjunctival scarring were examined to determine whether there is
evidence of ongoing transmission and pathology from ocular Chlamydia
infection.trachomatis (Ct) 
A total of 1511 individuals aged ≥1 year were enrolled from randomlyMethods: 
selected households in 13 villages in which >10% of children aged 1–9 years
had TF prior to a single round of azithromycin mass drug administration
undertaken six months previously. Blood was collected to be screened for
antibodies to the   antigen Pgp3. Tarsal conjunctival photographs wereCt
collected for analysis of scarring severity.
Anti-Pgp3 seropositivity was 18% in 1–9 year olds, sharply increasingResults: 
around the age of sexual debut to reach 69% in those over 25 years. Anti-Pgp3
seropositivity did not increase significantly between the ages of 1–9 years and
was not associated with TF (p=0.581) or scarring in children
(p=0.472). Conjunctival scars were visible in 13.1% of photographs. Mild
(p<0.0001) but not severe (p=0.149) scars increased in prevalence with age.
 Neither conjunctival scars nor lymphoid follicles were associatedConclusions:
with antibodies to   suggesting that they are unlikely to be a direct result ofCt,
ocular  infection Clinical signs of trachoma were prevalent in this populationCt . 
but were not indicative of the underlying rates of   infection. The current WorldCt
Health Organization guidelines for trachoma elimination indicated that this
population should receive intervention with mass distribution of antibiotics, but
the data presented here suggest that this may not have been appropriate.
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Introduction
Trachoma is responsible for approximately 1.9 million cases of 
visual impairment or blindness globally1. International partners 
have committed to elimination of trachoma as a public health 
problem by the year 2020 and the global elimination strategy is 
guided by the clinical signs trachomatous trichiasis (TT) and 
trachomatous inflammation–follicular (TF). The World Health 
Organization (WHO) recommends at least three years of mass 
drug administration (MDA) with azithromycin in districts with 
≥10% TF prevalence in 1–9 year-olds to treat the causative agent 
Chlamydia trachomatis (Ct)2.
A 2013 population-based prevalence survey (PBPS) cover-
ing two provinces (Temotu and Rennell & Bellona) of the 
Solomon Islands showed that the proportion of 1–9-year-old 
children with TF was moderately high (26.1%)3. In response to 
this and in accordance with WHO guidelines, MDA took place 
throughout the Solomon Islands in 2014 and the national 
program administered approximately 24,000 doses of azithro-
mycin (achieving coverage of approximately 80% in Rennell & 
Bellona, and 85% in Temotu). Data from the 2013 PBPS sug-
gested that whilst TF was prevalent, TT (0.1% of those ≥15 years), 
trachomatous inflammation—intense (TI; 0.2% of 1–9-year-
olds), and ocular infection with Ct (1.3% of 1–9 year-olds) were 
all rare3. Our recent survey of Kiritimati Island, Kiribati4, used 
the same tools and estimated more typically-matched values 
of TF and Ct infection prevalence (among children) at 28% 
and 24%, respectively. We therefore questioned the underlying 
biology of the TF signs that were observed in the Solomon Islands.
We hypothesised that the clinical signs in the Solomon Islands 
were not consistent with intense Ct transmission. We set out to 
investigate this hypothesis by returning to the same two prov-
inces of the Solomon Islands six months after MDA took 
place. This study used tests for two different persistent mark-
ers of previous Ct infection. The first was an enzyme-linked 
immunosorbent assay (ELISA) assay that measured antibod-
ies against the Ct antigen Pgp35,6. This tool has been used to 
assess transmission of both urogenital7 and ocular8 infections, 
including the study on Kiritimati Island, where we showed that 
there were strong associations between Ct infection, TF and 
anti-Pgp3 antibody levels. We also observed a rapid increase 
in Pgp3 seroprevalence throughout childhood years in that 
population4.
This study also assessed trachomatous scarring. Scarring, 
triggered by immuno-pathological responses to repeated 
cycles of infection, is an irreversible process that, like Ct 
seropositivity, is generally considered to be a persistent marker 
of previous ocular Ct infection. In trachoma, it is character-
ised by a gradual accumulation of scar tissue in the tarsal 
conjunctivae9, which typically begins to develop to the point of 
being visible in late childhood. Scarring is more commonly found 
in those who have experienced prolonged, severe inflammation and 
infection9–11. Very few young children in trachoma-endemic 
communities have signs of scarring, but as many as 10–30% of 
older children may do so12,13. Scarring progresses throughout 
a lifetime and, in severe cases, is the underlying cause of TT11. 
Assuming that trachoma was an endemic problem in this popu-
lation, we would expect to observe an age-dependent accumula-
tion of scarring, with an increasing proportional representation 
of severe scars with advancing age.
Methods
Ethics statement
The methods used in this study adhered to the tenets of the 
Declaration of Helsinki. Ethical approval for the study was 
granted by the London School of Hygiene & Tropical Medicine 
(LSHTM; 8402) and Solomon Islands National Health Research 
Ethics Committee (HRC15/03). Subjects aged 18 years or older 
gave written, informed consent to participate. A parent or guardian 
provided written, informed consent on behalf of those aged under 
18 years.
Study design
To enable comparison to pre-MDA data, only villages in 
Temotu and Rennell & Bellona provinces where baseline map-
ping had been conducted were eligible for inclusion. Due to their 
small respective populations (Temotu: n = 21,362; Rennell & 
Bellona: n = 3041), the two provinces were combined into one 
evaluation unit during baseline mapping. The survey took place 
in June–July 2015, six months after a single round of azithromy-
cin MDA had been delivered by the Solomon Islands National 
Trachoma Elimination Program.
Thirteen villages were selected in which more than 10% of the 
community (all ages) had previously had signs of TF3. We 
included numbers of villages in each province to reflect the pro-
portion of the total population of the two provinces combined 
(Temotu: 11 villages; Rennell & Bellona: 2 villages). The pro-
portions of active trachoma and infection cases in study villages 
before MDA were extracted from the full baseline dataset and 
are presented here for comparison.
This survey was powered to estimate the prevalence of 
anti-Ct antibody seropositivity in children aged 1–9 years. Based 
on the low prevalence of ocular Ct infection prior to MDA (1.3%), 
we expected the seroprevalence to be approximately 10%, in line 
with other communities with low Ct prevalence14. To estimate 
seroprevalence with ±5% precision at the 95% confidence level 
assuming a design effect of 2.65 (as utilised in the baseline study) 
at least 367 children were required15. In our pre-MDA PBPS 
survey, we examined a mean of 1.1 children per household and 
therefore estimated that 25 households in each of 13 clusters 
were needed to reach our sample size. All residents aged 1 year 
or above living in households drawn at random from a list of all 
households in a study cluster were eligible to participate.
Trachoma grading
Clinical grading of TF, TI and TT is a routine part of trachoma 
surveys; prevalence estimates of TF and TT are the basis for 
programmatic decisions on public health-level interventions. 
Similar standardisation does not exist for scar grading. Clinical 
grading according to the WHO simplified system16 was there-
fore used for TF, TI and TT, whilst photo-grading was used for 
scarring. TF, TI and TT grading was performed in the field by 
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one of two Global Trachoma Mapping Project (GTMP)-certified 
graders, wearing 2.5× binocular magnifying loupes17.
High-resolution digital photographs of the right tarsal conjuncti-
vae were graded for scarring using the modified WHO trachoma 
grading system18. Photographs were graded by two photo- 
graders who had previously achieved Fleiss’ Kappa scores for 
inter-observer agreement of >0.7 for F, P and C (Follicles, 
Papillae and Cicatricae) grades, compared to a highly- 
experienced trachoma grader. Photograph grading was under-
taken masked to field grading, laboratory results and the other 
photograph grader’s assessment. Discrepant grades were 
arbitrated by a third highly experienced grader. Grading was 
performed using “FPC_Grader”, an open source software tool 
based on R.
Specimens
Dried blood spots were collected for assessment of anti-Pgp3 
antibody level. Participants’ fingers were cleaned and then pricked 
with new, sterile lancets, and blood was collected onto filter 
paper calibrated to absorb 10 µL (CellLabs, Sydney, Australia). 
Filter wheels were air-dried for 4–12 hours before being sealed 
in plastic bags with desiccant sachets. These were refrigerated 
for up to one week and then stored at -20°C before shipping at 
ambient temperature to LSHTM, London, UK, where they were 
again stored at -20°C.
Swabs were passed three times (with a 120°-turn between each 
pass) over the right conjunctiva of children aged 1–9 years. The 
examiner and specimen manager took precautions to avoid 
cross contamination between participants or swabs in the field. 
In each village, one clean swab was passed within 20 cm of a 
seated participant and then processed identically to participant 
swabs to test whether cross contamination between swabs took 
place in the field. Swabs were refrigerated for up to one week 
and then stored at -20°C before shipping to LSHTM on dry ice 
for processing.
Serological and nucleic acid testing
Anti-Pgp3 antibody level was assessed using ELISA, as described 
elsewhere4,19. Optical density (OD) at 450 nm was measured 
using SpectraMax M3 photometric plate reader (Molecular 
Devices, Sunnyvale, USA) then normalised to a 20% dilution 
of high-titre (presumed positive) serum in low-titre (presumed 
negative) serum.
DNA was extracted from swabs with the QIAamp DNA mini 
kit (Qiagen, Manchester, UK). Samples were tested for Homo 
sapiens ribonuclease subunit (RPP30; endogenous control) and 
open reading frame 2 of the Ct plasmid (diagnostic target) using 
a previously evaluated droplet digital PCR assay20 with minor 
modifications21.
Data analysis
All data analyses were conducted using R 3.2.322. Pre- and 
post-MDA proportions were compared using Wilcoxon’s rank 
sum test. Fleiss’ Kappa scores were calculated using the ‘irr’ 
package in R. ddPCR tests for current ocular Ct infection were 
classified into negative and positive populations according to 
methods described previously20. Anti-Pgp3 antibody titre was 
divided into two populations using an expectation-maximisation 
finite mixture model6, with individuals classified serop-
ositive if their normalised OD was more than three standard 
deviations above the mean of the presumed-negative popula-
tion. Using this method, the threshold normalised OD value for 
positivity was 0.7997. Data from comparable studies in 
Bijagos Islands, Guinea-Bissau23, and Kiritimati Island, Kiribati4, 
are shown in Figure 2 and Figure 3, respectively. These have 
been reproduced under the Creative Commons Attribution 4.0 
International (CC-BY 4.0) and CC BY 3.0 IGO licenses, respec-
tively, to illustrate how patterns of antibodies and scars look 
in hyper-endemic settings.
Results
Study demographics
1511 people (46.3% male; 466 1–9-year-olds) aged 1 year and 
over were examined in 382 households from the 13 selected 
study villages. By comparison, the pre-MDA survey of the same 
villages yielded 1534 people (490 1–9-year-olds) in 
394 households. Data on non-participation were not collected in 
the June 2015 study, but the number enrolled was similar to that 
for the pre-MDA survey, suggesting a similar participation rate 
of around 90% on both occasions. In this study, there was a mean 
of 4 people per household aged 1 year and over, and a mean of 
1.2 children per household aged 1–9 years. After account-
ing for non-participants, this is similar to the means in the 2009 
Solomon Islands National Census (4.9 people of any age and 
1.4 children aged 1–9 years per household in Temotu, 4.4 people 
of any age and 1.1 people aged 1–9 years per household in 
Rennell & Bellona)24.
Clinical examination for trachoma
Prior to MDA, there were 167/490 (34.0%) cases of TF and 
1/490 (0.2%) case of TI in either eye in those aged 1–9 years in 
study villages3. We observed 66/466 (14.2%) cases of TF and no 
cases of TI in either eye after MDA, representing a decrease in 
TF of 58% (p<0.0001). Following MDA, 65% of TF cases were 
bilateral.
In the two villages enrolled in Rennell & Bellona, a slight 
increase in the prevalence of TF in either eye in those aged 
1–9 years following MDA was noted, but it was not statisti-
cally significant (11/60 [17.9%] before MDA to 14/78 [18.3%] 
after MDA; p=0.956). In contrast, in the 11 enrolled villages of 
Temotu, a substantial decrease in TF (from 156/430 [36.3%] 
before MDA to 52/388 [13.4%] after MDA; p<0.0001) was 
observed (Table 1).
No cases of TT were identified during this study.
Photographic assessment of trachoma
Of the right eye photographs that were collected, 1440/1511 
(95.3%) were suitable for grading conjunctival scarring. 188/1440 
(13.1%) photographs were graded as having visible scars (C>0), 
of which 127 were C1 (mild), 53 were C2 (moderate) and 
eight were C3 (severe). Four out of eight cases of C3 were found 
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Table 1. Characteristics of study populations before and after MDA, 13 selected communities 
of Temotu and Rennell & Bellona Provinces, Solomon Islands.
Characteristic Pre-MDA (October–
November 20133)
Post-MDA (June–July 
2015: this study)
p-value*
Number examined, all ages 1534 1511 -
Number examined aged 1–9 years 490 466 -
Number of households enrolled 394 382 -
% male of those examined 46.5 46.3 0.836
Ct infection in those aged 1–9 years** 5/462 (1.1%) 8/457 (1.8%) 0.259
Active trachoma in swabbed eye 160/490 (32.7%) 61/466 (13.1%) <0.0001
Ct infection in those aged 1–9 years 
with TF**
5/159 (3.1%) 6/61 (9.8%) 0.08
Median Ct infection load in positive 
specimens (plasmid copies/swab)
14,260 18,725 0.175
Ct: Chlamydia trachomatis.,
* Wilcoxon rank sum test.
** Swabs with no detectable human material were not included in this analysis.
in children aged 1–9 years, these photographs are shown in 
Figure 1. The photo-graders noted that whilst some conjuncti-
vae met the criteria for classification of C3 (i.e., there was clear 
scarring with distortion) these photographs also demonstrated 
the presence of features that are not typically associated with 
trachoma. In some cases, these were characterised by pronounced 
linear boundaries between heavily scarred conjunctiva and 
apparently healthy tissue (Figure 1C and 1D). Photo-graders 
noted that 4/53 (7.5%) C2 cases and 3/8 (37.5%) C3 cases looked 
atypical for trachomatous scarring. Of individuals with eyelid 
scarring considered typical for trachoma, 36/54 (67%) were 
seropositive, whereas 2/7 (29%) of those with atypical scar-
ring were seropositive. This difference in proportions was not 
significant (chi-squared test p=0.123), presumably because of the 
small numbers with atypical scarring.
The age-specific prevalence of scarring in the Solomon Islands 
is shown in Figure 2A. Of 435 photographs graded from 
children aged 1–9 years, 25 (5.7%) were graded as C>0. In 
311 adults aged >40 years who were examined, 74 (23.8%) 
had C>0 (65 cases of C1, 9 cases of C2, 0 cases of C3). We 
have reproduced published data from a comparable study in the 
Bijagos archipelago, Guinea-Bissau, where ocular Ct infec-
tions were common (22% of 1–9 year olds had detectable Ct 
infection)23. These data are included to demonstrate the contrast 
between photo-grading data sets from the Solomon Islands and 
Guinea-Bissau, the latter of which reflects the typical patterns 
of scar accumulation that would be expected in a setting where 
ocular Ct infection is hyperendemic (Figure 2B).
In the Solomon Islands, the proportion of people with C1 
increased with age (logistic regression p<0.0001), but the pro-
portion of people with more severe scarring (C2 or C3) did not 
(logistic regression p=0.149). There was also no significant 
association between having C>0 and gender (chi-squared test 
p=0.80). In Rennell & Bellona, 25/225 (11.1%) of photos were 
graded C>0, whereas in Temotu, 163/1215 (13.4%) of photos were 
graded C>0; the difference in scarring between provinces was 
not significant (chi-squared test p = 0.404).
Anti-Pgp3 serology
Dried blood spots were collected from 1499/1511 (99.2%) peo-
ple of all ages during the post-MDA survey; the other 12 people 
declined finger-prick. The distribution of normalised OD for 
all individuals, grouped into five-year age brackets, is shown in 
Figure 3A. This figure demonstrates the median normalised 
OD to be much higher in people aged >25 years than their 
younger counterparts. Overall, 633/1499 (42.2%) people were 
classified as seropositive. In children aged 1–9 years, the preva-
lence of anti-Pgp3 antibodies was 83/462 (18.0%). In 1-year-
olds alone, it was 5/47 (10.6%). The mean seroprevalence in those 
aged 6–10 years was not significantly higher than in those aged 
1–5 years (20.3% compared to 16.6%, chi-squared test p = 0.328) 
(Figure 3C). In Figure 3B, we have also included comparator 
data from Kiritimati Island, where the TF prevalence was simi-
lar but where the prevalence of Ct infection was much higher4. 
Among children aged 1–9 years, the rate and dynamics of accu-
mulation of seropositivity differed substantially between the 
Solomon Islands and Kiritimati (Figure 3B).
The largest increase in seroprevalence was observed between 
those aged 16–20 years and 21–25 years where seropreva-
lence rose significantly from 30.4% to 71.6% (chi-squared test 
p<0.0001). Of those aged over 25 years, 67.4% were seroposi-
tive. In the 16–20-year-old age group, the prevalence of seropos-
itivity amongst females was higher than in males (41.1% versus 
13.9%, chi-squared test p<0.0001). The seroprevalence 
among children in Rennell & Bellona was significantly higher 
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Figure 1. Conjunctival photographs graded as C3 from children aged (clockwise from top left) 7, 6, 1 and 8 years living in Temotu 
Province, Solomon Islands, June–July 2015. The children in photographs A, C and D are Pgp3 seronegative.
than that in Temotu (38.5% versus 13.8%; chi-squared test 
p<0.0001).
80.3% of Solomon Islands children with TF were seronega-
tive. 82.3% percent of children without TF were seronegative. 
There was no association between seropositivity and signs of TF 
in children aged 1–9 years (logistic regression adjusted for 
age and gender p=0.616). In those who were younger than 
the population median self-reported age of sexual debut 
(18 years25) there was no association between C grade and 
anti-Pgp3 OD (linear regression adjusted for age and gender 
p=0.453) or anti-Pgp3 positivity (logistic regression adjusted for 
age and gender p=0.472).
Ocular C. trachomatis infection
Positive endogenous control tests were obtained from 457/466 
swabs from children aged 1–9 years. The median load of the 
endogenous human RPP30 target was 33,500 copies, equiva-
lent to over 15,000 conjunctival cells. In this study, 8/457 
(1.8%) children had evidence of Ct plasmid DNA. Of the eight 
specimens from children who were positive for Ct, the median 
load was high at 18,725 plasmid copies/swab. This suggests that 
these were much less likely to be false positive results than had 
they been low load infections. 6 (9.8%) of the 61 children with TF 
also had Ct infection. We previously showed that, of 462 swabs 
from the pre-MDA study which passed quality control, 5/462 
(1.1%) had infection. All five infection cases came from children 
with active trachoma in the right eye (5/159, 3.1%). The median 
pre-MDA load of Ct infections in those villages was 14,260 
plasmid copies/swab3. Neither the difference between the 
pre- and post-MDA Ct prevalence nor the pre- and post-MDA 
Ct load were statistically significant (Wilcoxon rank sum test 
p=0.259 and p=0.175, respectively). The relationship between 
Ct infection, signs of trachoma and seropositivity was exam-
ined in children aged 1–9 years and is summarised in Table 2. 
7/8 cases of infection were in seropositive individuals 
(Figure 3C). All study villages had at least one case of TF, but 
infections were limited to five of the 13 villages studied. Two 
villages in Rennell & Bellona were the sites of five of the 
eight Ct infections identified during this study.
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Figure 2. (A) Age-specific prevalence of scarring (defined as C > 0), as identified by photograph grading, in 13 selected communities of 
Temotu and Rennell & Bellona Provinces, Solomon Islands, June–July 2015. (B) Published age-specific prevalence of scarring (defined 
as C > 0) from a comparator population in Guinea-Bissau, West Africa. Reproduced from Last et al.23 under CC-BY 4.0. In both plots, 
the numbers over each bar represent the size of each group.
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Figure 3. (A) Distribution of anti-Pgp3 antibody levels in Solomon Islanders resident in 13 selected communities of Temotu and Rennell & 
Bellona Provinces, divided into 5-year age groups. Red lines indicate age-group median, grey boxes represent inter-quartile range and 
whiskers represent the up to 1.5-times the inter-quartile range. For the purposes of this plot, those further than 1.5-times the inter-quartiles 
range from the upper/lower quartile are treated as outliers, denoted by black spots. (B) Black bars represent age-specific seroprevalence of 
anti-Pgp3 antibodies from children aged 1–9 years in study communities. Grey bars represent comparator population from Kiritimati Island, 
Kiribati, surveyed in November 2016 and tested using the same methodology as the Solomon Island samples. Reproduced from Cama 
et al.4 under CC BY 3.0 IGO. Red arrows represent 95% confidence interval of each age-specific seroprevalence estimate. (C) Blood anti-
Pgp3 antibody levels from children aged 1–9 years in selected communities.
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Discussion
Based on moderate estimates of province-level prevalence of 
TF, the Solomon Islands has (along with other Pacific Island 
states) been identified as having endemic trachoma. Whilst 
measures for trachoma elimination have already been deployed 
in Temotu and Rennell & Bellona, we have previously noted that 
TI, ocular Ct infection and late-stage disease (TT) are rare3. If 
the village level findings of the current study were replicated 
throughout the district, then TF would still be sufficiently preva-
lent to warrant continued intervention. The conjunctival scarring 
and serological data presented here, combined with previous Ct 
infection data, suggest that ocular Ct is scarce and is not being 
widely transmitted. TF is not associated with an appreciable 
burden of infection, severe scarring or TT in this population. 
Our most significant finding, which is that 80% of TF cases 
occur in people who are seronegative for antibodies against 
Ct, questions whether further rounds of MDA are warranted in 
this population.
In Kiritimati Island, we found that just 20.3% (23/119) of 
children with TF were seronegative according to the same 
ELISA test that was used here. We were unsurprised to find some 
individuals with TF were seronegative because (1) a propor-
tion of individuals who have primary infections will not yet have 
seroconverted and (2) anti-Pgp3 antibody responses may not 
be the same in all people due to natural variability in host 
responses, but the fact that 80% of TF cases in Solomon Islands 
were seronegative suggests that many cases are not caused by 
Ct infection. More important still is that in Kiritimati Island, 
children with TF were far more likely to be seropositive than 
those without TF. In the Solomon Islands, however, we not 
only found that most TF cases were seronegative, but that indi-
viduals with TF were no more likely to be seroreactive to Pgp3 
than their peers without TF. We can rule out the possibility that 
Solomon Islanders are collectively non-responsive to Pgp3 (for 
genetic reasons, for example) because the majority of the adult 
population do have antibodies against Pgp3. The most parsimo-
nious explanation of our findings is that TF in this population is 
caused by a factor other than Ct.
We found a small and non-significant increase in age-specific 
seroprevalence between young children (1–5 years) and older 
children (6–10 years), which suggests that children here occa-
sionally do encounter Ct infections. This is concordant with our 
previous data, which suggested that although ocular Ct strains 
are present in the Solomon Islands, they are rare3. This contrasts 
with the data from Kiritimati Island, where we saw that there 
was a substantial year-on-year increase in age specific serop-
ositivity (Figure 3B). The increase in seropositivity with age in 
this group was also very modest compared with that seen in 
hyper-endemic villages in Tanzania, where seropositivity has been 
observed to increase from approximately 25% to 94% between 
the ages of 1 and 6 years26. In the current dataset, there was a 
rapid increase in age-specific seroprevalence around the age of 
18 years, the self-reported median age of sexual debut in a 
nearby population25. The prevalence of urogenital Ct infection 
is known to be high in women attending antenatal clinics in the 
Solomon Islands25, which probably explains the high sero-
prevalence in adults as anti-Pgp3 antibodies do not distinguish 
between biovars. Exposure during parturition may also be a 
major contributor to the 10% of 1-year-olds in our study who had 
evidence of prior Pgp3 exposure27.
While seroreversion due to clearance of infection by MDA is 
a possible explanation for the low seroprevalence and absence 
of association of anti-Pgp3 antibodies with TF in the Solomon 
Islands, there is currently no evidence for complete serorever-
sion for Pgp3-specific antibodies7,26 after clearance of infection. 
It is, in any case, hard to imagine a biologically plausible situa-
tion in which seroreversion would fully account for the con-
trasts between serological data from Kiritimati and data from the 
Solomon Islands.
Table 2. Serological status compared to other tests for trachoma, 13 selected communities of Temotu 
and Rennell & Bellona Provinces, Solomon Islands, June–July 2015.
Comparator 1–9 year-olds ≥10 year-olds
Seronegative Seropositive Total Seronegative Seropositive Total
Ct infection 
by ddPCR*
Positive 1 7 8 - - -
Negative 373 76 449 - - -
TF Positive 53 13 66 13 9 22
Negative 326 70 396 474 541 1015
Scarring C0 333 77 410 414 418 832
C1 15 1 16 36 75 111
C2 3 2 5 16 32 48
C3 3 1 4 1 3 4
Ct: Chlamydia trachomatis; ddPCR: droplet digital polymerase chain reaction; TF: trachomatous inflammation—follicular.
* Swabs with no detectable human material were not included in this analysis.
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Whilst the proportion of people with mild scars increased with 
age, the proportion of those with more extensive or eyelid- 
distorting scars did not increase with age. Contrary to what might 
be expected in a trachoma-endemic community13, no eyelid-
distorting scars were found in 311 adults aged above 40 years. 
Some cases of severe scarring we observed in children were 
not typical of trachoma and were found in children who lacked 
Pgp3 reactivity (Figure 1, Table 2). There are other inflammatory 
conditions (e.g. adenoviral, acute haemorrhagic or membranous 
conjunctivitis) that may result in conjunctival scarring, although 
the pathology, incidence and prevalence of these are poorly 
understood and incompletely described28. It is also unclear 
whether the TF that we observed is directly linked to conjunctival 
scarring in this setting. In Temotu and Rennell & Bellona, the 
low prevalence of severe scars suggests that the proportion of the 
population at risk of developing TT is very low, although we 
cannot determine whether this might change in the future.
One limitation of all studies of tarsal conjunctival scarring is 
an element of diagnostic uncertainty when the scarring is very 
mild: determining whether it meets the C1 criteria is difficult. 
It is possible that this may be easier to judge from high qual-
ity digital photographs than during live examination using 2.5× 
loupes. In contrast, eyelid distortion, required to meet the criteria 
for C3, may be difficult to judge from a single, two-dimensional 
photograph. This can lead to disagreement between graders. 
However, subjectivity in determining the presence or absence of 
eyelid distortion is also present with field grading. Photography 
has the advantage that the images can be presented as empirical 
evidence (Figure 1) that can be scrutinised, appraised and 
regraded by third parties where field grades cannot. Photograph 
grading is the method of choice for studies of scarring severity or 
progression12,13,29.
The 13 communities included here were the most highly endemic 
of those surveyed in Temotu and Rennell & Bellona during the 
GTMP, with at least 15% of children aged 1–9 years living 
in selected villages having TF before MDA. In this study, we 
showed that the burden of TF in many of these villages dropped 
significantly following a single round of MDA, but still remained 
above the threshold for continued intervention. The drop in 
clinical disease was not reflected by a simultaneous drop in ocu-
lar Ct in children with TF, which actually increased slightly 
(although this increase was not statistically significant). From 
interventions in other settings, we might expect TF prevalence 
to have approximately halved six months after a single round of 
MDA, given 80% population coverage30,31. Azithromycin has 
anti-inflammatory and broad-spectrum antibiotic effects, which 
may help explain the observed decrease in clinical disease, but 
would of course only be effective in controlling a subset of 
bacterial genera. Given the method of village selection, regression 
to the mean would be another potential explanation for the fall in 
prevalence.
We observed regional variation across the study villages. Com-
pared to Temotu, we noted that MDA did not have as significant 
an impact on TF prevalence in Rennell & Bellona, that there 
were more children there who were seropositive and that there 
were more children with TF who also had infection. Our survey 
was not prospectively designed to assess these differences, 
and the subgroup size in Rennell & Bellona precluded more 
detailed analysis. Temotu is more similar to the rest of the Solomon 
Islands in terms of the geology and geography of the islands 
as well as in relation to the lifestyle and ethnicity of the majority 
of the inhabitants. Further studies on the localisation of trachoma 
in the islands are warranted.
The complex, multistage nature of trachoma makes it difficult 
to predict the outcome of any given intervention32. Data from 
cross-sectional surveillance tools used in isolation can be hard to 
interpret, especially given the prolonged persistence of TF after 
clearance of infection33. Some features of conjunctivitis in the 
Solomon Islands resemble trachoma, particularly the preva-
lent follicular inflammation and some of the severe conjunctival 
scarring. Crucially, we found that these clinical features were 
not co-endemic with TT at a prevalence that indicated an ongo-
ing public health problem. In this setting, we believe that tests for 
infection gave a better indication of the public health threat 
from trachoma than TF. A combined approach in which various 
age-specific markers of trachoma are assessed together across 
the complete age range of the population may prove useful for 
prioritising areas for intervention where the prevalence of TF 
alone does not coherently reflect trachoma’s public health 
importance.
Contrary to the WHO recommendation for treatment based 
solely on prevalence of TF, our data suggest that trachoma is not 
a public health problem in these villages. Whilst there have been 
substantial collateral benefits to local residents from having 
received MDA (such as on genital Ct34 and yaws35), further rounds 
of azithromycin MDA do not appear to be indicated for the pur-
poses of trachoma elimination. As the positive predictive value 
of TF for ocular Ct infection decreases globally in response to 
declining prevalence, it is likely that other regions and countries 
will be identified where a high prevalence of TF is not reflec-
tive of threat to vision and may not require MDA. WHO recom-
mendations for implementation of MDA and the SAFE strategy 
should be reviewed in the light of this evidence.
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This manuscript describes trachoma prevalence in the Solomon Islands over an almost 2 year period. The
data highlight the discrepancy between the presence of high TF rates, which would indicate that trachoma
is a public health problem in this area, while the rates of other signs of trachoma (ie. TI, TT) are very low to
none. The study is well designed and the manuscript well written. The concern raised by the authors that
the high TF rates seen may not actually reflect ongoing trachoma infection and thus MDA may not be
warranted are well supported by the data as is their suggestion that consideration be given to using
multiple markers of trachoma to determine whether or not intervention is needed.
 
I have some comments for the authors which I list below:
 
TS
In the Methods section the authors state that grading of TF, TI, and TT was done clinically and that
only scarring was graded by photographs. However, when they describe the inter observer
agreement for the grading they refer to the grading of F, P, and C (as per Dawson et al.). Could the
authors please report the following:
What the inter observer agreement for grading scarring alone was in this paper?
What percent of grades had to be adjudicated?
Where else this Dawson et. al scarring grading scheme applied to photographs has been
used/validated?
 
The authors followed the grading system of conjunctival scarring described by Dawson et al.; the
grade descriptions do not have clear cut offs. How did the authors modify this grading system for
the photographic graders? How did they determine the cut off between C1 and C2? How did they
determine shortening/distortion for C3 from photographs alone? Did they include looking for signs
of lid margin conjunctivilization as they state in their C3 example photograph? These are areas that
could lead to a great deal of disagreement between graders...
 
In the comparison population whose scarring data is presented in Figure 2 B, was the grading done
in the same way as in this paper, through photographs with two graders and an adjudicator? If so,
what was the inter-observer agreement? This information was not readily available in the paper
cited.
TF
Since the authors mention the kappa of F, P, and C, I wonder if they happened to grade follicles
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Since the authors mention the kappa of F, P, and C, I wonder if they happened to grade follicles
and papillae photographically? If so, how does this compare to the field grades? Given the
discrepancy between TF and all other signs of trachoma, having a way to ensure accurate field
grading of TF would be reassuring.
 
Do the authors have any hypotheses as to why the prevalence of TF might be so high in this
community if it is not due to trachoma (ie. higher incidence of viral etiologies, etc.)?
 
PGP3 Antibody
In the discussion the authors state that there is no evidence for complete seroreversion. Although I
agree with the overall conclusion that seroreversion cannot account for the differences in the data
that were observed, the authors may want to consider looking at/adding the following reference
which does support the presence of seroreversion: West et al. (2018) .
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The manuscript describes the results of a trachoma prevalence survey which measured clinical signs,
chlamydial infection, as well as anti-Pgp3 seropositivity among a population from the Solomon
providences of Temotu, and Rennell & Bellona. This report is one of a number of recent reports which
have examined this population in great detail, including through the use of conjunctival transcriptome
profiling and measures of microbial diversity. The manuscript is well written and the laboratory and
analytic techniques were appropriate for the main aims of the survey. Within this population, at both
baseline, and at the survey time-point described in this manuscript, the clinical signs of trachoma were
high enough to warrant interventions with antibiotics per WHO guidelines. However, other markers of
trachoma, such as low infection and seropositivitiy, as well as the very low prevalence of trichiasis,
suggested the possibility of alternative etiologies for the clinical signs (TF) of trachoma in these
providences. The findings of this study are important, as is the author’s call for the use multiple
age-specific markers of trachoma to help in prioritizing areas for intervention.
 
Major Comments
Given that a major finding here is that TF remained above 10%, while other trachoma indicators
suggested that trachoma was not a public health problem in these providences, it would strengthen
the manuscript if the authors provided some more information on whether or not they took
additional steps to ensure accurate grading of TF in the field. For example:
 
The authors state that one of two GTMP-certified graders did the grading for TF, TI, and TT. Please
state the month and year that this individual was certified for this particular survey, and what criteria
were used for certification. The kappas achieved were reported for the photograph grading, please
report for the field grading.
 
Second, it appears that this study used only one grader to capture field grades. Is there a concern
that the single chosen grader may have been a person who systematically overcalls TF (more
likely to call borderline cases TF)?
 
Were there any quality control steps taken to ensure the quality of the field TF grading? Given that
the discrepancy between TF and other markers of trachoma were discovered in these providences
at an earlier timepoint (Butcher et al 2016), and that this current survey for these providences was
already more thorough than standard trachoma surveys, the authors could have taken some steps
to ensure the quality of field grading. For example, was it possible to recheck a certain percentage
of TF cases while still in the field; how did the photo graders compare to the field graders for the TF
grade within this particular survey?
 
Minor comments
Under trachoma grading in the methods section, the authors discuss standardization of clinical
signs but only cite Thylefors in the section. That paper shows comparable inter- and intra-observer
variation for TF, TI and scarring (TS). Is there a different reference that can be used to support the
assertion that TF, TI, and TT are more “standardized” than scar grading?
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